Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2288-2302

  Babcook, Melissa A ^a   Shukla, Sanjeev ^a   Fu, Pingfu ^b   Vazquez, Edwin J ^a   Puchowicz, Michelle A ^a   Molter, Joseph P ^a   Oak, Christine Z ^b   MacLennan, Gregory T ^b   Flask, Chris A ^a   Lindner, Daniel J ^c   Parker, Yvonne ^c   Daneshgari, Firouz ^a   Gupta, Sanjay ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA; CHOLESTEROL; DOCETAXEL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN KINASE B; SERINE; SIMVASTATIN; THREONINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHRONOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE EPITHELIUM CELL; PROSTATE VENTRAL LOBE; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; BONE NEOPLASMS; CELL MOTION; DRUG EFFECTS; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL MOVEMENT; DRUG SYNERGISM; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIMVASTATIN;

EID: 84926661898     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0451     Document Type: Article

References (50)

1. Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 2012;118:2583-93.
2. Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control 2013;20:181-7.
3. Singer EA, Srinivasan R. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol 2012;30:S15-9.
4. El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013;5:25-40.
5. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLos ONE 2010;5: e14175.
6. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
7. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19:792-804.
8. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40.
9. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010;21:61-8.
10. Moreira DM, Anderson T, Gerber L, Thomas JA, Bañez LL, McKeever MG, et al. The association of diabetesmellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011;22:977-83.
11. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011;22:1545-52.
12. Moses KA, Utuama OA, Goodman M, Issa MM. The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis 2012;15:70-4.
13. Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta 2013;1835:219-29.
14. Gunter JH, Sarkar PL, Lubik AA, Nelson CC. New players for advanced prostate cancer and the rationalization of insulin-sensitizing medication. Int J Cell Biol 2013;2013:834684.
15. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2012;28:2653-9.
16. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2010;116:3389-98.
17. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG. Statin use and fatal prostate cancer: a matched case-control study. Cancer 2012;118:4046-52.
18. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
19. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 2013;19:6741-50.
20. Jespersen CG, Nørgaard M, Friis S, Skriver C, Borre M. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. Cancer Epidemiol 2014;38:42-7.
21. Lehman DM, Lorenzo C, Hernandez J, Wang CP. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012;35:1002-7.
22. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008;17:88-94.
23. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
24. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 2011;336:496-505.
25. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M, et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 2012;106:1689-96.
26. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C. Therapeutic potential of an anti-diabetic drug,metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev 2013;14:765-8.
27. Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-8.
28. Bederman IR, Foy S, Chandramouli V, Alexander JC, Previs SF. Triglyceride synthesis in epididymal adipose tissue: contribution of glucose and non-glucose carbon sources. J Biol Chem 2009;284:6101-8.
29. Shukla S, Bhaskaran N, Babcook MA, Fu P, MacLennan GT, Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis 2014;35:452-60.
30. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
31. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2:329-33.
32. Marshall J. Transwell invasion assays. Methods Mol Biol 2011;769:97-110.
33. Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, et al. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. J Steroid Biochem Mol Biol 2013;133:30-42.
34. Fang D, West RH, Manson ME, Ruddy J, Jiang D, Previs SF, et al. Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on the de novo cholesterol synthesis. Respir Res 2010;11:61.
35. Morris MJ, Gilbert JD, Hsieh JY, Matuszewski BK, Ramjit HG, Bayne WF. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:1-8.
36. Zhang J, Rodila R, Gage E, Hautman M, Fan L, King LL, et al. High-throughput salting-out assisted liquid/liquid extraction with acetonitrile for the simulataneous determination of simvastatin and simvastatin acid in human plasma with liquid chromatography. Anal Chim Acta 2010;661:167-72.
37. Uçaktürk E. The development and validation of a gas chromatography-mass spectrometry method for the determination of metformin in human plasma. Anal Methods 2013;5:4723-30.
38. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
39. Krycer JR, Brown AJ. Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis? PLoS ONE 2013;8:e54007.
40. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol 2013;86:339-50.
41. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
42. Soltys CLM, Kovacic S, Dyck JRB. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006;290:H2472-9.
43. Kayampilly PP, Menon KM. Follicle-stimulating hormone inhibits adenosine 5′-monophosphate-activated protein kinase activation and promotes cell proliferation of primary granulosa cells in culture through an Akt-dependent pathway. Endocrinology 2009;150:929-35.
44. Pulinilkunnil T, He H, Kong D, Asakura K, Peroni OD, Lee A, et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 2011;286:8798-809.
45. Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.J Clin Invest 2013;123:2907-20.
46. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50.
47. Di Buono M, Jones PJH, Beaumier L, Wykes LJ. Comparison of deuterium incorporation and mass isotopomer distribution analysis for measurement of human cholesterol biosynthesis. J Lipid Res 2000;41:1516-23.
48. Mener DJ. Prostate specific antigen reduction following statin therapy: mechanism of action and review of the literature. IUBMB Life 2010;62:584-90.
49. Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 2011;125:421-30.
50. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, et al. Characterization and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011;10:126.